CDT Equity

CDT Equity P/FCF

The P/FCF (Price-to-Free-Cash-Flow Ratio) of CDT Equity (CDT) as of Oct 20, 2026 is -0.12. In the previous year, P/FCF (Price-to-Free-Cash-Flow Ratio) was -0.22 — a change of -45.80% (higher).

P/FCF

-0.12

YoY

-45.80%

Last updated:

P/FCF (Price-to-Free-Cash-Flow Ratio) of CDT Equity is 2025 -0.12 . P/FCF (Price-to-Free-Cash-Flow Ratio) of CDT Equity was 2024 -0.22 . It decreases by -45.80% higher compared to the previous year.

The CDT Equity P/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/FCF
Date
P/FCF
Jan 1, 2021
-0.99 USD
Jan 1, 2022
-0.94 USD
Jan 1, 2023
-0.28 USD
Jan 1, 2024
-0.22 USD
Jan 1, 2025
-0.12 USD
The CDT Equity P/FCF history
YEARP/FCFYoY
-0.12-45.80%
-0.22-20.63%
-0.28-70.67%
-0.94-5.07%
-0.99—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

CDT Equity Stock analysis

What does CDT Equity do? CDT Equity Inc generates revenue through the development and commercialization of clinical assets targeting unmet medical needs. The company focuses on disease-agnostic life science solutions, with key assets including AZD1656, a glucokinase activator for diabetes mellitus and Hashimoto’s Thyroiditis treatment, and AZD5904, a myeloperoxidase inhibitor for idiopathic male infertility. These assets are licensed for use in autoimmune diseases, immunodeficient conditions, and specific medical applications like uveitis, preterm labor, and renal transplant rejection. Pharmaceutical companies and healthcare providers purchase these clinical assets for research and therapeutic development. The company’s revenue streams derive from licensing agreements and commercial partnerships for its pipeline products. AZD1656 is positioned as a treatment option for Hashimoto’s Thyroiditis and Graves’ disease, while AZD5904 targets idiopathic male infertility. The firm’s focus on autoimmune and immunodeficient conditions aligns with healthcare providers seeking innovative therapies for complex patient populations. Licensing deals with pharmaceutical firms drive the primary revenue model. CDT Equity Inc’s business model centers on developing and licensing clinical assets across multiple therapeutic areas. Its pipeline includes AZD1656 for diabetes and thyroid conditions, and AZD5904 for infertility and autoimmune disorders. The company collaborates with healthcare providers and pharmaceutical partners to advance these assets toward commercialization, generating income through licensing fees and future product sales. CDT Equity is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CDT Equity stock

P/FCF (Price-to-Free-Cash-Flow Ratio) of CDT Equity is -0.12 in 2025.

P/FCF (Price-to-Free-Cash-Flow Ratio) of CDT Equity changed from -0.22 to -0.12, representing a -45.80% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/FCF (Price-to-Free-Cash-Flow Ratio) CDT Equity since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Free-Cash-Flow ratio measures how much investors pay for each unit of free cash flow. A lower ratio may indicate better value.

P/FCF = Market Capitalization / Free Cash Flow

To evaluate P/FCF (Price-to-Free-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/FCF (Price-to-Free-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/FCF (Price-to-Free-Cash-Flow Ratio)'s CDT Equity with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — CDT Equity

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — CDT Equity